Bristol-Myers Squibb (NYSE:BMY) will post its Q3 2019 quarterly earnings results before the market opens on Thursday, October 31st. Analysts expect Bristol-Myers Squibb to post earnings of $1.05 per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.
Shares of Bristol-Myers Squibb stock opened at $55.59 on Tuesday. Bristol-Myers Squibb has a one year low of $42.48 and a one year high of $57.37. The stock’s fifty day moving average is $51.20 and its 200 day moving average is $47.57. The stock has a market cap of $88.94 billion, a P/E ratio of 13.97, a P/E/G ratio of 1.28 and a beta of 0.72. The company has a debt-to-equity ratio of 1.51, a quick ratio of 3.75 and a current ratio of 3.88.
The business also recently announced a quarterly dividend, which will be paid on Friday, November 1st. Investors of record on Friday, October 4th will be issued a $0.41 dividend. The ex-dividend date of this dividend is Thursday, October 3rd. This represents a $1.64 dividend on an annualized basis and a yield of 2.95%. Bristol-Myers Squibb’s dividend payout ratio is currently 41.21%.
In other Bristol-Myers Squibb news, Director Robert J. Bertolini purchased 11,000 shares of the business’s stock in a transaction on Wednesday, July 31st. The stock was acquired at an average price of $44.72 per share, for a total transaction of $491,920.00. Following the purchase, the director now owns 11,397 shares of the company’s stock, valued at approximately $509,673.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.13% of the company’s stock.
A number of equities analysts recently commented on the company. Atlantic Securities raised Bristol-Myers Squibb from a “neutral” rating to an “overweight” rating and set a $63.00 target price on the stock in a report on Wednesday, August 14th. ValuEngine lowered Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a research note on Friday. TheStreet upgraded Bristol-Myers Squibb from a “c+” rating to a “b-” rating in a research note on Wednesday, September 18th. UBS Group increased their price target on Bristol-Myers Squibb from $51.00 to $53.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 23rd. Finally, Bank of America began coverage on Bristol-Myers Squibb in a research note on Wednesday, October 16th. They issued a “buy” rating and a $60.00 price target for the company. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $55.86.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Featured Article: Dividend
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.